Venus Remedies (VENUSREM) Fundamentals 2026 — P/E 21.9x, Revenue Analysis | SniperIQ
Venus Remedies (VENUSREM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹2,255 Crore, trading at ₹1686.90 on the NSE. This SniperIQ fundamentals page covers Venus Remedies's valuation (P/E 21.9x, P/B 3.4x), profitability (net margin 13.5%), revenue (₹770 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Venus Remedies's market cap?
Venus Remedies (VENUSREM) has a market capitalization of approximately ₹2,255 Crore, trading at ₹1686.90 on the NSE. Market cap moves with the live share price.
What is Venus Remedies's P/E ratio?
Venus Remedies's trailing twelve-month P/E ratio is 21.9x, with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Venus Remedies?
Venus Remedies runs a net profit margin of 13.5%, a gross margin of 41.6%, and an operating margin of 15.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Venus Remedies generate?
Venus Remedies reported revenue of ₹770 Crore for fiscal year 2026, with net income of ₹103 Crore and earnings per share (EPS) of 76.89. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Venus Remedies pay a dividend?
Venus Remedies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Venus Remedies financially healthy?
Venus Remedies carries a debt-to-equity ratio of 0.02x and a current ratio of 2.44x, with a market beta of 0.90. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Venus Remedies a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Venus Remedies (VENUSREM) the key facts are: market cap ₹2,255 Crore, P/E 21.9x, revenue ₹770 Crore, 52-week range 424-2044.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Venus Remedies's full fundamentals live
Get Venus Remedies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.